Onchilles Pharma Raises $7 Million Series A to Advance Drug Candidates to Activate Newly Discovered Broad-Acting Anticancer Pathway

11 Jun, 2021

Onchilles Pharma Raises $7 Million Series A to Advance Drug Candidates to Activate Newly Discovered Broad-Acting Anticancer Pathway
Photo by Startaê Team on Unsplash

– Onchilles Pharma announced a $7m Series A financing from LYZZ Capital and includes a $500k investment from the University of Chicago’s Startup Investment Fund.
– The proceeds of the financing will be used to develop first-in-class therapeutics to activate a novel pathway of the innate immune system with potential for universal anti-cancer activity, independent of genetic mutation.
– Research published in today’s issue of Cell is the first to describe this pathway where human neutrophils release catalytically active neutrophil elastase, called ELANE, to selectively kill many cancer cell types while sparing non-cancer cells.
– ELANE is an entirely new treatment paradigm with the potential to have broad and selective cancer killing activity regardless of genetic mutation or anatomical origin.

Biopharma Biotechnology North America Pharmaceutical
Crunchbase icon

Content report

The following text will be sent to our editors: